The content on this site is intended for healthcare professionals only
Dr Krishnansu Sujata Tewari presents data on a randomised phase III study assessing two different chemotherapy regimens with or without bevacizumab during a press conference at the 2013 ASCO Annual Meeting.
The study found that adding bevacizumab prolongs overall survival by an average of four months compared to chemotherapy alone. The study represents the first time a targeted drug has significantly prolonged overall survival for women with metastatic or relapsed cervical cancer.
Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer
Zanidatamab improves PFS and OS in first-line HER2-positive metastatic gastric cancer
Optimal management of gastric cancers
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Advancements in head and neck cancer treatment in India
Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer
Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results
Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS compared to trifluridine/tipiracil monotherapy in mCRC
